A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

Eli Lilly and Company8 enrolled

Overview

The main purpose of this study is to evaluate how much of the study drug (LY3372689), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

[¹⁴C]-LY3372689DRUG

Administered orally.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male participants who are overtly healthy as determined by medical evaluation * Have a body mass index within the range 18.5 to 32.0 kilograms per meter squared (kg/m²) * Males who agree to use highly effective/effective methods of contraception for 14 weeks following the dose of LY3372689 may participate in this trial. Exclusion Criteria: * Have a clinically significant abnormal blood pressure and/or pulse rate as determined by the investigator at screening or check-in * Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs * Have evidence of significant active neuropsychiatric disease, as determined by the investigator * Have participated in \>3 radiolabeled drug studies in the last 12 months

Locations (1)

LabCorp CRU, Inc.

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Urinary Excretion of LY3372689 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered